Proton therapy is effective and safe for prostate cancer treatment, according to new research from the University of Florida Proton Therapy Institute. The findings from seven studies were presented Oct. 28-31 in Boston during the American Society for Radiation Oncology (ASTRO) 54th Annual Meeting, the premier scientific conference on radiation…Continue
Added by Peter Hofland, PhD on November 6, 2012 at 6:00pm — No Comments
Two studies led by The University of Texas MD Anderson Cancer Center have found that proton therapy preserves the quality of life, specifically urinary and bowel function, in men treated with this targeted radiation modality for prostate cancer.
Both studies, led by Andrew K. Lee, M.D., M.P.H., associate professor in MD Anderson's Department of Radiation Oncology, will be presented in a poster session at the 54th…Continue
Added by Peter Hofland, PhD on October 29, 2012 at 1:00pm — No Comments
A study published in the May 2012 issue of Cosmetic Dermatology may offer hope for patients with nonmelanoma skin cancer of eye lids. The study looked at 11 patients who received radiation therapy for nonmelanoma skin cancers of the eyelid in the last three years. Each of the patients involved in the study, led by Gary L. Marder, DO, FAOCD, received hyperfractionation treatments (where radiation is divided into smaller doses…Continue
Added by Peter Hofland, PhD on May 3, 2012 at 4:00am — No Comments
The Virginia G. Piper Cancer Center at Scottsdale Healthcare has added a hematopoietic stem cell (HSC) transplant cancer treatment program through its new Cancer Transplant Institute.
The new cancer treatment program is expected to attract transplant patients from greater Phoenix, across Arizona and the southwestern United States. HSC transplants are primarily used to treat patients with aggressive…
Added by Peter Hofland, PhD on February 24, 2012 at 8:30am — No Comments
New research presented at the 53rd Annual Meeting of the American Society of Hematology being held in San Diengo, CA, December 10 - 13, concludes that patients with limited-stage Hodgkin lymphoma treated with a standard chemotherapy regimen have better overall survival rates compared with those receiving a radiation-based treatment.
Patients with limited-stage Hodgkin lymphoma (HL) are often treated with…
Added by Peter Hofland, PhD on December 11, 2011 at 9:30am — No Comments
HIV-infected patients are at increased risk for cancer as a result of both their impaired immune system and lifestyle factors, such as smoking, according to researchers at Kaiser Permanente.
The study, which appears in the current issue of Cancer Epidemiology, Biomarkers and Prevention, is among the first to directly compare the…
Added by Peter Hofland, PhD on November 22, 2011 at 11:00am — No Comments
Patients with recurrent metastatic non-small cell lung cancer (NSCLC) have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to advancing cancer research.
A research team at…
Added by Peter Hofland, PhD on November 9, 2011 at 4:00pm — No Comments
New research into the treatment of gastrointestinal cancers – and novel ways to predict recurrence and response to chemotherapy – were presented during the eighth annual Gastrointestinal Cancers Symposium, held January 20-22, 2011, at The Moscone West Building in San Francisco.
One study, a Phase II Radiation Therapy Oncology Group (RTOG) trial, showed that combining chemotherapy with intensity-modulated radiation therapy (IMRT) is just as effective after…
Added by Peter Hofland, PhD on January 20, 2011 at 3:30pm — No Comments
At the San Antonio Breast Cancer Symposium (SABCS) held this weekend a study conducted by HistoRx Inc and the University of Calgary was selected for discussion by the breast cancer specialists assembled for the conference. This study of 568 patients treated at the University of Calgary had several clinically relevant conclusions.
The study results showed…
Added by Peter Hofland, PhD on December 13, 2010 at 12:00pm — No Comments
A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a lifesaving therapy for women with hormone sensitive early-stage breast cancer.
Dawn L. Hershman, M.D., M.S., associate professor of medicine and epidemiology and co-director of the Breast…
Added by Peter Hofland, PhD on December 11, 2010 at 1:30pm — No Comments
A combination of three drugs, lapatinib (Tykerb®/Tyverb® , GlaxoSmithKline), an orally active, reversible, small-molecule tyrosine kinase inhibitor that potently inhibits both HER1 and HER2 tyrosine kinase activity, trastuzumab (Herceptin®, Genentech), a humanized monoclonal antibody directed against HER2, and paclitaxel (…Continue
Added by Peter Hofland, PhD on December 10, 2010 at 11:30am — No Comments
Follicular lymphoma (FL) is the most common type of non-Hodgkin Lymphoma (NHL). In 2010 an estimated 65,540 people in the US were diagnosed with NHL, and follicular lymphoma accounts for between 15 to 20%t of these case. Overall, about 35% of all NHLs in the USA, and 22% worldwide, are diagnosed as FL. 
Follicular lymphoma, also called 'indolent' or 'low-grade' lymphoma, is a slow-growing neoplasm arising from follicle center-derived B cells, both…
Added by Peter Hofland, PhD on December 5, 2010 at 9:00am — No Comments
Women planning on taking hormone therapy for the treatment of menopausal symptoms should be aware of a possible increased risk for ovarian cancer, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held in Philadelphia from November 7-10, 2010.
“This study is consistent with previous recommendations that say if women are going to take hormones they should only take them in the short term,” said…
Added by Peter Hofland, PhD on November 9, 2010 at 10:30pm — No Comments
Added by Peter Hofland, PhD on October 19, 2010 at 10:00am — No Comments
Added by Peter Hofland, PhD on October 12, 2010 at 12:30pm — No Comments
Added by Peter Hofland, PhD on July 12, 2010 at 9:00am — No Comments
Added by Peter Hofland, PhD on June 28, 2010 at 7:00am — No Comments
Added by Peter Hofland, PhD on June 11, 2010 at 11:30pm — No Comments
Added by Peter Hofland, PhD on June 5, 2010 at 11:30am — No Comments
Added by Peter Hofland, PhD on December 14, 2009 at 4:00pm — No Comments